This is the Technical Web Site of ELISHA Systems Ltd.
ELISHA was the acronym of the EU project funded under the Nanotechnology Theme of Framework 6. The project was completed on 30th June 2007 and the technology is being commercialised by ELISHA Systems Ltd., a new SME based in the UK.
Main Contacts for ELISHA Systems Ltd:
Technical Enquiries
Dr Tim Gibson Telephone 01924 829560
Business Enquiries
Dr Graham Johnson Telephone 01298 70891
Registered Address
Sigma House, Burlow Road, Buxton, Derbyshire, SK17 9JB, UK
Company number 6142403
ELISHA Systems Ltd is developing Biochips and Point-of-Care Instrumentation based on the ELISHA immunosensor technology.
Since 2008, ELISHA Systems Ltd has been developing the ELISHA technology to be commercially viable. The basic technology comprises disposable single measurement biochips and an electrochemical reader that is being designed to be a Point-of-Care device.
Biochips can be configured in different ways:
1) Single analyte configuration – using 2 working electrodes to generate the specific signal and to correct for non-specific binding
2) Multiple analyte configuration – using multiple working electrodes to detect a number of target analytes from a single sample.
The analytical sequence to measure target analytes is essentially the same for each type of biochip.
Add sample to biochip – incubate for several minutes – read concentration.
The incubation time depends on the target and concentration range of the target analyte, but it is of the order of 5 to 20 minutes for most target analytes measured to date.
The development has demonstrated the feasibility of the antibody based biochips to detect many more analytes in a wide range of sample matrices. Some examples are given below.
ANALYTE MATRIX SENSITIVITY
Meningococcus Whole human blood 10 cells in 100µl blood
Myoglobin Human serum 10 picogrammes per ml
Fluoroquinoline antibiotics Bovine milk 1 nanogramme per ml
MRSA PBS / non-ionic detergent 10 cells per ml
To date most protein and carbohydrate biomarkers are quantifiable down to picogramme per ml levels in 20 minutes. Most bacterial samples seem to have a detection limit of 10 cells per ml or 10 cells per sample (e.g. for the miningococcus example, 100µl of whole blood containing 100cells per ml gave a consistently measurable response). Recently viruses have been detected and quantified directly using a virus antibody. In addition target analytes have been detected and quantified in neat human saliva and neat human urine working with third party clients.
ELISHA Systems Ltd has World-wide patent protection in the area of AC Impedance interrogation of protein biochips and has IP in an alternative electrochemical detection technique developed in the ELISHA project.
ELISHA Systems Ltd is looking to discuss potential collaborations with interested third parties who have analyte panels they would like to transfer onto the ELISHA platform. Please contact Dr Tim Gibson or Dr Graham Johnson using the contact details above.
Latest News
|
02/Jun/2011
ELISHA Systems Ltd in a new TSB Project for Rapid Diagnosis of MRSA and STD's
MRSA is one of the antibiotic resistant bacteria that is often implicated in Healthcare Acquired Infections. Working with FERA and Sterilin Ltd, ELISHA Systems Ltd is developing a Bacto-chip able to detect MRSA in point-of-care situations. Also N Gonorrhoea will be a second target organism for the technology.
|
...read more
|
|
|
01/Jun/2011
Dr Tim Gibson at the Cheltenham Science Festival 10th June 5.45pm
On Friday 10th June in the Town Hall at Cheltenham there is a presentation on Mobile Health. Dr Tim Gibson, Technical Director of ELISHA Systems Ltd will be one of 3 presentors discussing the potential of healthcare linked to mobile telecommunication technology, such as mobile phones and how it may be possible in the future to make field diagnostic systems based around low, cost simple to use biosensors.
|
...read more
|
|
|
08/Jun/2010
ELISHA Systems Ltd at the Biosensors World Congress in Glasgow, May 2010
Dr Tim Gibson presented a poster at the Biosensors World Congress in Glasgow, Scotland in May 2010. A pdf of the poster is available here.
|
...read more
|
|
|